At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness of a Structured Intervention to Optimize Both the Use of Mirabegron, a β3 Receptor Agonist, and Facilitate Its Discontinuation: a Quasi-experimental Study
In Brief
A clinical study evaluating Review the use of mirabegron and its discontinuation for Overactive Bladder Syndrome. Completed, enrolled 1,932 participants.
Detailed Summary
This study was a multicentre, quasi-experimental design, controlled, before-and-after trial to estimate the effectiveness related to the review of mirabegron use and, if appropriate, its discontinuation. Intervention group: Patients with mirabegron prescription assigned to any of the 17 primary health care centers (PHC) located in the northern area of Barcelona. Control group: All the other patients assigned to any of the other 34 health care centers in Barcelona belonging to the Catalan Institut of Health (CIH). The structured intervention included initiatives with general practitioners and urologists/gynaecologists, management support from health care authorities, and monthly feed-back monitoring to general practitioners (GPs). The follow-up period was 12 months, from January 1st to December 31st, 2017.
Study Details
Timeline
Interventions
A structured intervention was designed consisting of four major sections: * General practitioners: information and training with written material and patient-centred prescribing. * Specialized hospital care: information regarding the intervention for urologists and gynaecologists. * Management support with the definition of a structured strategy. * Monthly monitoring of the intervention.